|Articles|October 13, 2009

Should Low-Risk MRSA Patients be Screened?

In an Oct. 8 guest editorial in the British Medical Journal, Michael Millar, a consultant microbiologist in the Department of Infection at The London NHS Trust, asks, “Should we screen low-risk patients for methicillin-resistant Staphylococcus aureus?” Millar asserts that a Department of Health policy requiring all hospital patients to be screened for MRSA breaches ethical guidelines.

Millar explains that since April 2009, all patients electively admitted to hospitals in Britain must be screened for MRSA, and this requirement will be extended to emergency admissions from next year. Millar notes, “Although the policy is presented as a population screening program, most people who are screened will gain little benefit and may be harmed. The justification for universal screening is therefore unclear.”

Millar says that the Department of Health “has taken increasingly stringent measures since 2001 to reduce the burden of infection associated with MRSA. The measures seem to have been successful, with the numbers of MRSA bloodstream infections falling by more than half from 2003 to 2008. However, the overall numbers of healthcare associated infections reported to the English Health Protection Agency rose substantially, raising questions about the focus on MRSA.”

Reference: BMJ 2009;339:b4035

 


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.